Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481054 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL6928401 | 0.79 | TRPV4 (0.39) | TRPA1CYP11B1CYP11B2 | |
| SCHEMBL480244 | 0.79 | ABCC9 (0.33) | — | |
| SCHEMBL3513144 | 0.74 | PGR (0.42) | — | |
| SCHEMBL8812550 | 0.72 | CYP19A1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL481070 | 0.72 | FAAH (0.31) | FAAHTRPA1 | |
| SCHEMBL3512198 | 0.71 | PTGDR2 (0.36) | FAAHCYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL30452122 | 0.71 | PTGDR2 (0.36) | FAAHCYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL481069 | 0.71 | CACNA1H (0.34) | APLNRFAAHCYP11B1CYP11B2ADRB2 | |
| SCHEMBL20642688 | 0.69 | ADRB2 (0.39) | CYP11B1CYP11B2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1817301-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | APLNR 152/4885FAAH 1561/4885TRPA1 316/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | APLNR 327/4885FAAH 691/4885TRPA1 155/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | APLNR 327/4885FAAH 691/4885TRPA1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.